748771-26-8

Basic information

• Product Name: Phenol, 4-[5-(4-fluorophenyl)-3-isoxazolyl]-
• CAS NO: 748771-26-8
• Molecular Formula: C15H10FNO2
• Molecular Weight: 255.248
• Mol File: 748771-26-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Phenol, 4-[5-(4-fluorophenyl)-3-isoxazolyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 4-[5-(4-fluorophenyl)-3-isoxazolyl]-(748771-26-8)
• EPA Substance Registry System: Phenol, 4-[5-(4-fluorophenyl)-3-isoxazolyl]-(748771-26-8)

Safety Data

• Hazardous Substances Data: 748771-26-8(Hazardous Substances Data)

Upstream product

• 766-98-3 1-ethynyl-4-fluorobenzene 
• 699-06-9 4-hydroxybenzaldehyde oxime 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 123-08-0 4-hydroxy-benzaldehyde 
• 7397-22-0 1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one 
• 38435-51-7 N-hydroxy-4-methoxy-benzenecarboximidoyl chloride 
• 123-11-5 4-methoxy-benzaldehyde 
• 3717-21-3 p-methoxyl benzaldoxime 
• 748771-22-4 5-(4-fluoro-phenyl)-3-(4-methoxy-phenyl)-isoxazole 

Downstream Products

• 1603988-60-8 2-(4-(5-(4-fluorophenyl)isoxazol-3-yl)phenoxy)acetic acid 

Relevant articles and documents

Synthesis of some novel substituted phenylisoxazol phenoxy 2-methylpropanoic acids and there in vivo hypolipidemic activity

The novel series of phenylisoxazol phenoxy 2-methylpropanoic acid derivatives were synthesized and evaluated for their in vivo hypolipidemic activity by triton WR-1339-induced hyperlipidemia in rats. The newly synthesized compounds 5a and 5i showed significant decrease in the serum TCH, TG, LDL and VLDL along with an increase in serum HDL levels as compared to standard drug Fenofibrate. The treated groups also showed significant decrease in the atherogenic index, TC:HDL risk ratios compared to cholesterol-induced hyperlipidemic control group. These molecules indeed have the potential to be developed as antihypolipidemic molecules.

Synthesis and in-vivo hypolipidemic activity of some novel substituted phenyl isoxazol phenoxy acetic acid derivatives

The present study was undertaken to evaluate in-vivo hypolipidemic activity of a novel series of 2-methyl-2-(substituted phenyl isoxazol)phenoxyacetic acid derivatives by triton induced hyperlipidemia in rats. The newly synthesized compounds 5a, 5d and 5g showed significant decrease in the serum TCH, TG, LDL and VLDL along with an increase in serum HDL levels as compared to standard drug Fenofibrate. The treated groups also showed significant decrease in the atherogenic index and increase in % protective activity compared to control group.